Geoffrey A. Behrens

Geoffrey A. Behrens

Auto-generated profile, based on publicly available information

Geoffrey A. Behrens

DKMS Life Science Lab, Dresden, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2011 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
GBGeoffrey A. Behrens
Geoffrey A. Behrens
AHAnke Hummel
Anke Hummel
SPSantosh K. Padhi
Santosh K. Padhi
SSSebastian Schätzle
Sebastian Schätzle
Uwe T. BornscheuerUwe T. Bornscheuer
Uwe T. Bornscheuer

16 July 2011 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
JRJessica Rehdorf
Jessica Rehdorf
GBGeoffrey A. Behrens
Geoffrey A. Behrens
GNGiang-Son Nguyen
Giang-Son Nguyen
RKRobert Kourist
Robert Kourist
Uwe T. BornscheuerUwe T. Bornscheuer
Uwe T. Bornscheuer

13 November 2013 in ChemCatChem
Verified
Journal Article
Closed access
PDF file
SHSilke Hackenschmidt
Silke Hackenschmidt
EMEva J. Moldenhauer
Eva J. Moldenhauer
GBGeoffrey A. Behrens
Geoffrey A. Behrens
MGMartin Gand
Martin Gand
Ioannis PavlidisIoannis Pavlidis
Ioannis Pavlidis
Uwe T. BornscheuerUwe T. Bornscheuer
Uwe T. Bornscheuer

13 February 2020 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
GBGeoffrey A Behrens
Geoffrey A Behrens
MBMichael Brehm
Michael Brehm
RGRita Groß
Rita Groß
JHJana Heider
Jana Heider
JSJürgen Sauter
Jürgen Sauter
VLVinzenz Lange
Vinzenz Lange
Buccal swab sampling constitutes an attractive noninvasive alternative to blood drawings for antibody serostatus assays. Here we describe a method to determine the cytomegalovirus immunoglobulin G (CMV IgG) serostatus from dried buccal swab samples. Upon solubilization, CMV IgG is determined by an ELISA assay specifically adapted to cope with low IgG concentrations. The derived CMV titer is normalized against the total protein concentration to adjust for incorrectly or less efficiently sampled buccal swabs. Assay parameters were optimized on a set of 713 samples. Validation with 1784 samples revealed distinct results for > 80% of samples with 98.6% specificity and 99.1% sensitivity. Based on the analysis of 1.2 million samples we derived age- and sex-stratified CMV prevalence statistics for Germany, Poland, United Kingdom, and Chile. To confirm accuracy of the assay in routine operation, the CMV status of 6518 donors was reassessed by independent laboratories based on conventional blood samples revealing 96.9% specificity and 97.4% sensitivity. The assay accurately delivers the CMV IgG serostatus from dried buccal swab samples for > 80% of the participants. Thereby it provides a noninvasive alternative to plasma-based CMV monitoring for nondiagnostic purposes such as hematopoietic stem cell transplantation donor screening or population studies.

1 February 2019 in Human Immunology
Verified
Journal Article
Open access
YHYvonne Hagenlocher
Yvonne Hagenlocher
BWBeatrix Willburger
Beatrix Willburger
GBGeoffrey A. Behrens
Geoffrey A. Behrens
ASAlexander H. Schmidt
Alexander H. Schmidt
YIYuri Ioffe
Yuri Ioffe
JSJürgen Sauter
Jürgen Sauter
A total of 1075 Russians from the Russian part of Karelia were genotyped at high-resolution for the human leukocyte antigen loci HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 using next generation sequencing methods. The haplotypic and allelic profiles as well as Hardy-Weinberg proportions of this population sample were evaluated. As the most frequent 6-locus haplotype, A*03:01 g ∼ B*07:02 g ∼ C*07:02 g ∼ DRB1*15:01 g ∼ DQB1*06:02 g ∼ DPB1*04:01 g was identified with an estimated frequency of 3.5%. No deviation from Hardy-Weinberg Equilibrium was detected at any of the loci studied. The HLA genotypic data of the population sample reported here are available publicly in the Allele Frequencies Net Database under the population name "Russia Karelia" and the identifier AFN3430.

5 September 2020 in BIOspektrum
Verified
Journal Article
Open access
PDF file
AKAnja Klussmeier
Anja Klussmeier
GBGeoffrey A. Behrens
Geoffrey A. Behrens
VLVinzenz Lange
Vinzenz Lange
Timely identification and isolation of affected individuals is one of the most important factors to control spreading of the newly emerged SARS-CoV-2. Consequently, it is crucial to maintain sufficient sample capacities in diagnostic laboratories. Here, we present a high-through-put approach for PCR-based SARS-CoV-2 testing. The implementation of sample pooling reduces costs and workload, especially in times with low population prevalence.